Sulfobutylether β- Cyclodextrin
β-Cyclodextrin is a cyclic oligosaccharide containing seven D-(+)-glucopyranose units attached by a(1→4) glucoside bonds. Sulfobutylether b-cyclodextrin is an anionic β-cyclodextrin derivative with a sodium sulfonate salt separated from the hydrophobic cavity by a butyl spacer group. The substituent is introduced at positions 2, 3, and 6 in at least one of the glucopyranose units in the cyclodextrin structure.
| Supplier | CD Formulation |
|---|---|
| Product # | PE-0597 |
| Pricing | , Inquire for price |
| product1 | Stabilizers |
| Molecular Formula | C42H70-nO35·(C4H8SO3Na)n |
| Molecular Weight | 2163 (where n = approximately 6.5) |
| Applications | Cyclodextrins are crystalline, nonhygroscopic, cyclic oligosaccharides derived from starch. Sulfobutylether b cyclodextrin is an amorphous, anionic substituted β-cyclodextrin derivative; other substituted cyclodextrin derivatives are also available. Sulfobutylether β-cyclodextrin can form noncovalent complexes with many types of compounds including small organic molecules, peptides, and proteins.It can also enhance their solubility and stability in water. |
| Safety | Sulfobutylether β-cyclodextrin is derived from b-cyclodextrin, which is nephrotoxic when administered parenterally. However, studies have shown that sulfobutyletherβ-cyclodextrin is well tolerated at high doses, when administered via intravenous bolus injections, orally, and by inhalation.Up to 9 g/day may be administered by IV infusion in a licensed voriconazole formulation.The safety following high doses of sulfobutylether β-cyclodextrin intravenous administration in humans is continually being investigated. Sulfobutylether β-cyclodextrin has been subjected to an extensive battery of in vitro and in vivo genotoxicity and pharmacological evaluations. No genotoxic or mutagenic changes were observed with sulfobutylether β-cyclodextrin administration. Sulfobutylether β-cyclodextrin is biocompatible and exhibits no pharmacological activity. It is rapidly eliminated unmetabolized when administered intravenously. |
| Incompatibilities | The preservative activity of benzalkonium chloride is reduced in the presence of sulfobutylether β-cyclodextrin. |
| Synonyms | β-Cyclodextrin sulfobutylether, sodium salt; Captisol; (SBE)m-betaCD; SBE7-b-CD; SBECD; sulfobutylether-β-cyclodextrin, sodium salt |
| CAS Number | 1824100-00-0 |
| Category | Biocompatibility enhancer; Osmotic Agents; Solubilizing Agents; Stabilizing Agents; Tablet and Capsule Diluent; Viscosity-increasing Agents; Water activity reducing Agents |
| Chemical Name | β-Cyclodextrin sulfobutylether, sodium salt |
| Grade | Pharmceutical Excipients |
| Administration route | SC, oral, inhalation, nasal and ophthalmic, IV and IM |
| Dosage Form | SC, oral, inhalation, nasal and ophthalmic, IV and IM injectable products |
| Stability and Storage Conditions | Sulfobutylether β-cyclodextrin is stable in the solid state and should be protected from high humidity. It should be stored in a tightly sealed container in a cool, dry place. It will reversibly take up moisture without any effect on the appearance of the material at humidities up to 60% RH.Equilibration at RH values above 60% will result in deliquescence.Once in this state, the material can be dried, but will give a glasslike product. This water absorption behavior is typical of amorphous hygroscopic materials. Sulfobutylether β-cyclodextrin is stable in aqueous solutions at values above about pH 1. It can degrade in highly acidic (pH < 1) solutions, particularly at elevated temperatures, producing the ring opened form, followed by hydrolysis of the a(1→4) glucoside bonds. Sulfobutylether b-cyclodextrin solutions may be autoclaved. |
| Source and Preparation | Sulfobutylether b-cyclodextrin is prepared by alkylation of β-cyclodextrin using 1, 4-butane sultone under basic conditions. The degree of substitution in b-cyclodextrin is controlled by the stoichiometric ratio of β-cyclodextrin to sultone used in the process. |